The cost data in this study show that the cost of blood glucose monitoring is the primary cost driver across both countries and may pose a greater barrier to high-quality T1DM treatment than the type of insulin used (i.e., analogue versus human). This evidence concerns the gene INS and type 1 diabetes mellitus.